AMRX is the ticker for Amneal Pharmaceuticals, Inc., a Nasdaq-listed developer and manufacturer of generic and specialty medicines. The $24 central target is calculated from seven current analyst price targets: UBS at $28, Oppenheimer at $27, Leerink Partners at $25, JPMorgan at $25, Goldman Sachs at $24, Piper Sandler at $21, and Barclays at $20. The arithmetic mean is about $24.3, rounded to $24, with a $20–$28 range.
The ratings cluster is decisively bullish. UBS raised its target to $28 from $25, citing second-quarter results and upcoming biosimilar and generic launches. Oppenheimer, which initiated at $27, describes Amneal at a "fundamental inflection." Leerink and JPMorgan point to the Affordable Medicines portfolio, biosimilars, and the Crexont and lanreotide franchises. Goldman Sachs lifted its target to $24, while Barclays, the most conservative at $20, flags the pending gLanreotide approval as a potential catalyst. The range is wide, which reflects genuine disagreement about how quickly new launches convert into durable earnings power.
With the stock near $20.14, reaching $24 requires roughly a 19% advance—a substantial move from a name already up sharply, with a 52-week range of about $11.30 to $21.68. The company generated roughly $3.2 billion in trailing revenue and a market capitalization near $7 billion, with a forward P/E (price-to-earnings ratio) near 17 but a trailing P/E near 50, reflecting expectations for significant earnings growth.
The path toward the target depends on execution: converting biosimilars and specialty launches into revenue and EBITDA (earnings before interest, taxes, depreciation, and amortization) growth while stabilizing generic retail pricing. The stock recently pulled back after its third-quarter report despite solid fundamentals, underscoring how much of the story is already priced into a sharp year-to-date rally.
The stock is trading within sight of its 52-week high of $21.68, which now acts as a nearby resistance level; a decisive move above it would represent a fresh multi-year high. The recent post-earnings pullback found footing near $19.45, which serves as near-term support. Below that, the broader uptrend remains intact well above the $11.30 52-week low, but the gap between price and the $24 target means the advance would likely require fundamental confirmation rather than momentum alone.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always state the period explicitly. Investors should watch quarterly earnings and guidance, the progression of the biosimilars and lanreotide launches, the pending gLanreotide approval decision, and any revisions to fiscal 2026 EBITDA and EPS guidance. Changes in generic drug pricing, interest rates, and sector sentiment toward healthcare names are also relevant.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For those following AMRX and similar names, the tool offers a data-driven way to track evolving momentum alongside traditional research.
The question of whether Amneal Pharmaceuticals can reach $24 centers on whether it can deliver on a growth narrative that is only partly reflected in today's price. The $24 target is the average of seven current analyst targets spanning $20 to $28, implying a substantial but not extreme 19% move. Bullish analysts see biosimilars, Crexont, and lanreotide driving a fundamental inflection, while the wide target range reflects real uncertainty about generic retail execution, leverage, and a demanding valuation. The near-term catalysts—earnings, biosimilar launches, and the gLanreotide decision—will determine whether the stock can build on its sharp rally. As with any equity, the target is a research reference point, not a guarantee, and outcomes will depend on execution and market conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with AMPH. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To AMRX | 1D Price Change % | ||
|---|---|---|---|---|
| AMRX | 100% | +0.47% | ||
| AMPH - AMRX | 46% Loosely correlated | -1.09% | ||
| VTRS - AMRX | 43% Loosely correlated | +1.76% | ||
| ANIP - AMRX | 39% Loosely correlated | +5.10% | ||
| TEVA - AMRX | 38% Loosely correlated | -1.33% | ||
| SUPN - AMRX | 37% Loosely correlated | +4.09% | ||
More | ||||
| Ticker / NAME | Correlation To AMRX | 1D Price Change % |
|---|---|---|
| AMRX | 100% | +0.47% |
| Pharmaceuticals: Generic industry (81 stocks) | 9% Poorly correlated | -0.76% |